CARLSBAD, Calif.– Thermo Fisher Scientific has announced the launch of its Oncomine™ Comprehensive Assay Plus on the Ion Torrent™ Genexus™ System, offering clinical research laboratories a powerful new tool for rapid and comprehensive genomic profiling (CGP). The integrated solution enables next-day results and aims to accelerate precision medicine efforts in oncology.
The Oncomine Comprehensive Assay Plus analyzes 517 genes and detects a wide range of genomic alterations, including single-nucleotide variants, insertions and deletions, copy number variations, and gene fusions. It also measures key genomic signatures such as tumor mutational burden (TMB), microsatellite instability (MSI), and homologous recombination deficiency (HRD). While the assay has already been available on Thermo Fisher’s Ion GeneStudio™ S5 system, its availability on the Genexus platform brings full CGP capabilities into a highly automated, end-to-end workflow.
“We have been waiting for this complete and rapid CGP solution that includes all the relevant biomarkers including TMB, MSI and HRD,” said Hector M Alcaraz, MS, founder of Imagene Health, SA de CV and an early-access user of the assay on the Genexus System. “This will make CGP more accessible to our local markets so that we can drive the future of precision medicine forward.”
The Genexus System is a fully integrated next-generation sequencing (NGS) platform designed to deliver fast, accurate results with minimal hands-on time. By automating sample preparation, sequencing, and data analysis, the system allows laboratories to perform CGP with reduced complexity and faster turnaround.
“In recent years, new genomic insights have played an essential role in advancing our understanding of human health and driving novel drug development,” said Kathy Davy, president of Clinical Next Generation Sequencing at Thermo Fisher Scientific. “The addition of the Oncomine Comprehensive Assay Plus on the Genexus System brings the benefits of rapid CGP to more labs, empowering researchers to leverage more comprehensive results at a much faster pace and accelerate what could be life-saving research.”
The combination of advanced assay design and seamless automation positions Thermo Fisher’s latest offering as a significant step forward in making precision oncology more accessible and efficient for clinical researchers worldwide.
